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Chemokine-induced stem cell recruitment is a promising strategy for post myocardial infarction treat-
ment. Injection of stromal cell-derived factor 1 (SDF1) has been shown to attract bone marrow-derived
progenitor cells (BMPCs) from the blood that have the potential to differentiate into cardiovascular cells,
which support angiogenesis, enabling the improvement of myocardial function. SDF1-GPVI bi-speciﬁc
protein contains a glycoprotein VI (GPVI)-domain that serves as an anchor for collagen type I (Col I)
and III, which are exposed in the wall of injured vasculature. In this study, we generated a cytocompatible
hydrogel via photo-crosslinking of poly(ethylene glycol) diacrylate that serves as a reservoir for SDF1-
GPVI. Controlled and sustained release of SDF1-GPVI was demonstrated over a period of 7 days.
Release features were modiﬁable depending on the degree of the crosslinking density. Functionality of
the GPVI-domain was investigated using a GPVI-binding ELISA to Col I. Activity of the SDF1-domain was
tested for its CXCR4 binding potential. Preserved functionality of SDF1-GPVI bi-speciﬁc protein after
photo-crosslinking and controllable release was successfully demonstrated in vitro supporting the
implementation of this drug delivery system as a powerful tool for therapeutic protein delivery in the
treatment of cardiovascular ischemic disease.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Myocardial infarction (MI) and its subsequent long term effects,
including chronic ischemic heart disease, account for the greatest
cause of morbidity and mortality in developed countries [1].
Myocardial necrosis after ischemic conditions leads to alterations in
cardiac extracellular matrix (ECM) composition [2,3]. These alter-
ations are initiated by a strong inﬂammatory response triggered by
cardiomyocyte death. During the inﬂammatory phase of the
reparative response after MI, macrophages scavenge dead cellsepartment of Cell and Tissue
y. Tel.: þ49 711 970 4082;
ofer.de (K. Schenke-Layland).
Ltd. This is an open access article ufrom wounded tissue. The following proliferative phase in
myocardial repair is characterized by the repopulation of the
infarcted area by myoﬁbroblasts, which produce large amounts of
ECM proteins including collagens. Crosslinking of these collagens
takes place during the maturation phase leading to scar formation,
which completes the reparative response [3]. Alterations in cardiac
ECM composition changes the ventricular geometry [3], which is
followed by a volume overload and subsequently leads to the
elongation of cardiomyocytes and thinning of the ventricular wall
[4]. Additionally, matrix metalloproteinase-activated degeneration
of collagen crosslinks leads to further dilation of the ventricle [4].
Subsequent impairment of cardiac diastolic and systolic function
progressively reduces the cardiac output, which ultimately leads to
chronic heart failure (HF) [4]. Based on the increasing socio-
economic burden of ischemic cardiovascular disease, research has
expanded rapidly in the ﬁeld of cardiovascular regenerative med-
icine over the last few years and several therapeutic strategies havender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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muscle in patients is still an unmet goal and organ transplantation
remains the only option to treat severe HF [5].
One strategy to enhance cardiac function post MI is the appli-
cation of adult stem cells such as bone marrow-derived mesen-
chymal progenitor cells (BMPCs) via injection [1,6]. BMPCs have
been identiﬁed as an eligible cell type for a cardiovascular stem
cell-based therapy, although their potential to differentiate into all
cell types of the cardiovascular lineage including cardiomyocytes is
controversially discussed [7]. It is hypothesized that improvement
of cardiac function after BMPC injection is due to paracrine effects
such as secretion of cytokines and proangiogenic growth factors
[8]. Cardiac patches have been used to replace damaged myocar-
dium with natural heart-derived substrates that support that
cardiac contractile function [9]. Furthermore, cardiac patches have
been applied successfully to enable a localized delivery of adult
stem cells and improved stem cell engraftment into the heart
[8,10] as these patches provide structural cues that enhance stem
cell viability during the delivery process [11]. Another relevant
application for cardiac patches is the localized and controlled
release of therapeutic proteins such as vascular endothelial growth
factor [12]. Preservation of cardiac contractile function is partly
achieved by a reduction in infarct size and an enhanced capillary
density [13], which in turn has been achieved by the delivery of
angiogenic growth factors [12] or chemokines [14] via hydrogels.
Among these, poly(ethylene glycol) (PEG)-based hydrogels have
been identiﬁed as excellent drug delivery systems [15,16]. Their
hydrophilicity and low protein binding characteristics enable an
effective release of incorporated drugs and support the mainte-
nance of protein bioactivity [15]. One promising chemokine to
induce neovascularization is stromal cell-derived factor 1 (SDF1). It
binds to the C-X-C chemokine receptor type 4 (CXCR4), also known
as fusin or CD184, which is expressed on the surface of hemato-
poietic and cardiovascular progenitor cells [17]. CXCR4-expressing
cells are thought to play a crucial role in angiogenesis post MI
[18,19]. Therefore, several studies aimed on the utilization of SDF1
through a number of delivery mechanisms including adenoviral
gene delivery [20], intra-myocardial protein injection [21] or via
protein-releasing hydrogels [14,22,23]. Although the prolonged
presence of pure SDF1 has been shown to result in improved
cardiac function after MI in animal models [18,21,24], optimal
delivery features allowing a sustained release of bioactive SDF1
remains to be developed. To reach an accumulation of SDF1 in the
affected area, Ziegler et al. designed a recombinant bi-speciﬁcFig. 1. Effect of the bi-speciﬁc protein SDF1-GPVI. Schematic of a blood vessel (A) before a
collagen types I and III via its GPVI-domain (green) and recruits BMPCs from the circulating
this ﬁgure legend, the reader is referred to the web version of this article.)protein, which contains a soluble form of the platelet collagen
receptor glycoprotein VI (GPVI) [25] in addition to the SDF1
domain (SDF1-GPVI) [13]. In the pathophysiology of MI, collagens
and other ECM proteins from the sub-endothelial matrix are
exposed to the vessel lumen of coronary arteries most often after
the disruption of an atherosclerotic plaque [26]. GPVI binds to the
collagen triple helix, which is comprised of the repetitive amino
acids triplet glycine-proline-hydroxyproline, in all three collagen
chains. Most notably, these residues are most frequent at the N-
termini of collagen types I (Col I; a1) and III (a1) and the C-ter-
minal domain of Col I (a1). Col I and III are highly present in the
sub-endothelium of vessel walls [27], thus serving as docking sites
for bi-functional proteins containing a GPVI domain [13,28] and
subsequently lead to accumulation of SDF1-GPVI at the site of
vascular injury (Fig. 1). The effect of the bi-speciﬁc protein SDF1-
GPVI after direct injection has been shown for post-MI treatment
in a mouse MI model [13,29]; however, we hypothesize that a
sustained delivery of SDF1-GPVI may hold great potential to
further improve cardiac function. Hence, the aim of this study was
to generate a drug releasing hydrogel based on photo-crosslinked
PEG diacrylate (PEGda), which serves as a reservoir for the SDF1-
GPVI protein. The potential of this hydrogel to provide a sus-
tained and tunable release of SDF1-GPVI as well as preserving the
bioactivity of the protein was assessed in vitro.
2. Materials and methods
2.1. Cell culture
T17b murine endothelial progenitor cells (mEPCs) were kindly provided by Dr.
A.K. Hatzopoulos (Department of Cell and Developmental Biology, Vanderbilt Uni-
versity, USA) and cultured as previously described [30,31] using Dulbecco’sModiﬁed
Eagle Medium (DMEM) high glucose (BE12-741F, Lonza, Verviers, Belgium) con-
taining 20% fetal calf serum (FCS; 10270, Life Technologies, Paisley, UK), 100 U/ml
penicillin and 100 mg/ml streptomycin (15140, Life Technologies), 1% non-essential
amino acids (11140, Life Technologies) and 0.1 mM b-Mercaptoethanol (28625,
Serva, Heidelberg, Germany). Cells were grown to 80% conﬂuence.
Human endothelial colony forming cells (ECFCs; 00189423, Lonza, Basel,
Switzerland) were cultured in Endothelial Cell Growth Medium (ECGM; C-22010,
Promocell, Heidelberg, Germany), supplemented with ECGM supplement mix (C-
39215, Promocell), 10% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin and 1%
Glutamin (25030, Life Technologies). Mediumwas exchanged every 2 days and cells
were passaged when reaching a conﬂuence of 70e80%.
2.2. Hydrogel fabrication
Hydrogels were prepared by dissolving 0.15 g/ml PEGda (average Mn 6000;
701963, Sigma Aldrich, Taufkirchen, Germany) in Dulbecco’s Phosphate Buffered
Saline (DPBS; 14190, Life Technologies). The photoinitiator Irgacure 2959 (I 2959; 2-nd (B) after endothelial lesion. At the area of endothelial injury, SDF1-GPVI binds to
blood with the SDF1-domain (purple). (For interpretation of the references to color in
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was dissolved in 70% ethanol (Merck, Darmstadt, Germany). The concentration of I
2959 used for hydrogel fabrication was 750 mg/ml unless stated otherwise. For
release and functionality assays, the polymer solution was blended either with
bovine serum albumin (BSA; A9576, Sigma Aldrich) or SDF1-GPVI at the provided
concentrations. The solution was crosslinked at a wavelength of 365 nm with a UV
light intensity of 5mW/cm2 using an UV crosslinker (60-BLX-365, PEQLAB, Erlangen,
Germany). Hydrogel stability was measured by studying weight loss over 4 weeks.
Hydrogels were incubated in DPBS at 37 C and 5% CO2 and weighed at deﬁned time
points.
2.3. MTT assay
Hydrogels without incorporated protein were prepared as described above
(n ¼ 3) and washed with DPBS to prevent the gels from drying. For cytotoxicity
studies, 5  104 mEPCs were seeded onto the hydrogel. To allow a proper cell
attachment, mEPCs were incubated on the hydrogel surface for 30 min at 37 C and
5% CO2. Subsequently, mEPC medium was added into each well until the hydrogel
was covered. mEPCs cultured in 12-well plates at the same density and medium
volume served as controls. After 4 days of incubation, viable cells were visualized via
a Thiazolyl Blue Tetrazolium Bromide (MTT) solution (M2128, Sigma Aldrich).
2.4. Release kinetics
Hydrogels with photoinitiator concentrations of 750, 1000 and 5000 mg/ml were
prepared as described above (n ¼ 3). In addition, 3200 mg/ml BSA was introduced
prior to the UV gelation process. After crosslinking, the hydrogels were washed and
incubated with DPBS at 37 C and 5% CO2 in order to enable BSA release. Superna-
tants were removed at 0, 2, 4, 12, 24, 48, 168 and 816 h and frozen immediately
at 80 C. To quantify the released protein, a Bradford assay was performed ac-
cording to the manufacturer’s protocol (Roti-Nanoquant K880.2, Carl Roth, Karls-
ruhe, Germany). After 5 min incubation at room temperature, the absorption was
measured at 595 nm using an InﬁniteM 200 Pro reader (TECAN, Groedig, Austria).
2.5. SDF1-GPVI release
The release of SDF1-GPVI was assessed using hydrogels with a surface area of
10.1 cm2 (n¼ 3). Hydrogels were prepared by adding either 50 mg/ml or 100 mg/ml
of the protein to the PEGda solution. After washing, hydrogels were incubated with
DPBS over 7 days at 37 C and 5% CO2. The supernatant was collected from each
hydrogel after 48, 96 and 168 h. To quantify the SDF1-GPVI concentration in the
supernatant, a human IgG ELISA assay (human IgG ELISA kit, 0801182, Immunotek,
Buffalo, USA) was performed according to the manufacturer’s protocol. This ELISA
kit, which detects human IgG, was determined suitable as the protein SDF1-GPVI
exhibits a human IgG2 domain. Absorption was measured using the Inﬁnite
M200 Pro reader.
2.6. Immunoﬂuorescence staining of a human artery vessel wall
Carotid arteries were obtained from patients undergoing bypass surgery. These
studies were in accordance with institutional guidelines and were approved by the
Ethics Committees of the Eberhard-Karls-University Tübingen and the Land-
esärztekammer Baden-Württemberg (IRB #694/2012BO1 and F-2011-068). Human
arteries were harvested and processed as previously described [32]. Tissue sections
of human artery vessel walls were deparafﬁnized and rehydrated. After antigen
retrieval in a microwave oven for 8 min in 10 mM Tris, 1 mM ethyl-
enediaminetetraacetic acid (EDTA), 0.05% Tween 20 (pH 9.0) and 10 mM citrate so-
lution in PBS (pH 6.0), slides were processed as described before [33] and stained
using a primary pan-laminin antibody (1:50; ab11575, Abcam, Cambridge, UK).
Following secondary antibody incubation using an Alexa Fluor 594-conjugated
goat anti-rabbit IgG (1:250; A-11037, Life Technologies), slides were exposed to
DAPI solution (124653, Merck) and mounted in ProLong Gold antifade reagent
(P36394, Life Technologies). Fluorescence images were acquired using an Axio
Observer microscope (Carl Zeiss, Göttingen, Germany).
2.7. Functionality of GPVI binding
An ELISA assay was performed to characterize the GPVI binding of released
SDF1-GPVI to Col I (n ¼ 3). SDF1-GPVI, solubilized in DPBS, was biotinylated via
incubation with 0.5 M EZ Link Sulfo NHS LC Biotin (21335, Pierce, Rockford, USA) for
1 h at 27.5 C. Biotinylation was stopped using 10 mM Trizma Base (T1503, Sigma
Aldrich) at pH 9.5. Well plates were coated with 10 mg/ml Col I, which was isolated
from bovine skin as previously published [34]. Control wells were coated using
10 mg/ml murine laminin-111 (354232, BD Biosciences, Bredford, USA) or 10 mg/ml
Albumin Fraction V BSA (A13910500, Applichem, Darmstadt, Germany) at 4 C over
night. Plates were washed with Tris-Buffered Saline (TBS) and incubated with a 1%
BSA solution for 90 min to block unspeciﬁc binding sites. SDF1-GPVI was diluted in
TBS containing 5% BSA. To enable protein binding to Col I, BSA or laminin-111, plates
were incubated with the desired concentration of SDF1-GPVI over 90 min. After
washing with 4-(2-hydroxythyl)-1-piperazineethanesulfonic acid buffer, the protein
was ﬁxed with a 2.5% glutaraldehyde solution (ZC881439041, Merck) for 10 min.Plates were rinsed with TBS followed by an incubation period of 90 min with an
ExtrAvidin antibody (1:1000; E2636, Sigma Aldrich). The substrate 4-
Nitrophenylphosphat disodium salt hexahydrate (N9389, Sigma Aldrich) was
added to visualize protein binding. Time of incubation ranged between 5 and 25min
to reach reasonable binding signals. The reaction was stopped by addition of 1.5 M
NaOH (A1551, AppliChem) and absorptionwasmeasured using an ELISA plate reader
(Synergy HTMulti-Mode Microplate Reader, BioTek, Bad Friedrichshall, Germany).
Incubation was performed at room temperature unless stated otherwise.
2.8. Staining of the CXCR4 receptor on ECFCs
Human ECFCs were seeded onto glass chamber slides (177402, Thomas Scien-
tiﬁc, Swedesboro, USA) coatedwith 0.01% gelatin (G1890, Sigma Aldrich) at a density
of 5  104 cells per chamber and cultured over night at 37 C and 5% CO2. After 16 h,
cells attached to the glass slides, whichwere thenwashedwith DPBS and ﬁxed using
4% paraformaldehyde (11762.01000, Morphisto, Frankfurt, Germany) for 10 min at
room temperature. After DPBS washing, unspeciﬁc binding sites were blocked by
incubation with goat IgG-containing blocking buffer for 30 min. A CXCR4 antibody
(1:100, ab2074, Abcam) was incubated over night at 4 C. The secondary anti-rabbit
IgG antibody (1:250, Alexa Fluor 488, A-11034, Invitrogen) was incubated for
25 min in the dark. After cells were washed with DPBS and exposed to DAPI, the
slides were mounted using ProLong Gold antifade reagent. Fluorescence images
were obtained using an Axio Observer microscope.
2.9. SDF1 binding to the CXCR4 receptor
ECFCs were seeded onto the gelatin-coated chamber slides with a density of
1.7  105 cells per ml. After an incubation period of 16 h, ECFCs were rinsed with
DPBS and unspeciﬁc binding sites were blocked by incubation with goat IgG con-
taining blocking solution for 30 min. Supernatants containing 240 ng released SDF1-
GPVI collected from the hydrogels (n ¼ 9) were added to each chamber. 240 ng of
fresh, non-released SDF1-GPVI served as positive control, whereas the negative
control was treated with DPBS only. After incubation, cells were washed and sub-
sequently ﬁxedwith 4% paraformaldehyde for 10min. A FITC-conjugated human IgG
antibody (1:50; 109-095-098, Jackson Immuno Research, West Grove, USA) was
used to determine protein binding. After 90 min incubation in the dark, cells were
washed again and exposed to DAPI for 15 min. Images were acquired using the Axio
Observer microscope system and ﬂuorescence expression was quantiﬁed as gray
value intensity (GVI) per cell using ImageJ software (National Institutes of Health,
Bethesda, USA).
2.10. Data analysis
All data are presented as means  standard deviations. Statistical signiﬁcance
was determined by one-way analysis of variance (ANOVA) using Origin software
(OriginPro 8G, Northhampton, UK). p  0.05 was deﬁned as statistically signiﬁcant.
3. Results
3.1. Generation of a hydrolytically stable non-cytotoxic PEGda
hydrogel
UV crosslinking was employed to generate a solid and trans-
parent PEGda hydrogel (Fig. 2AeC). Swelling properties and hy-
drolytic stability of the PEGda hydrogels generated using 750 mg/ml
I 2959 were assessed in a weight loss study (Fig. 2D). PEGda
hydrogels showed a signiﬁcant increase in weight within the ﬁrst
2 h (0 h: 454  24 mg versus 2 h: 557  28 mg; p ¼ 0.0009), fol-
lowed by a constant value over the observed time of 816 h in total.
After a period of 4 weeks, no signiﬁcant weight loss of PEGda
hydrogels occurred, indicating a 4-week hydrolytic stability. Cell
viability and cytocompatibility of the hydrogel was assessed after 4
days utilizing an MTT assay (Fig. 2E,F). The blue color indicated that
mEPCs, which were seeded onto the hydrogel, were able to
metabolize the MTT. Therefore, the hydrogel had no cytotoxic
impact on the cells under the used experimental conditions.
3.2. Protein release from the hydrogel
In order to identify the suitable parameters for hydrogel
fabrication, BSA was used as a control protein, which was encap-
sulated in PEGda hydrogels fabricated using different concentra-
tions of I 2959. A Bradford assay was performed to monitor BSA
release from the hydrogels with an average surface area of
Fig. 2. Schematic of hydrogel fabrication: (A) aqueous polymer-I 2959 solution prior to gelation and (B) the solid hydrogel after UV-crosslinking. (C) Photograph of a solid PEGda
hydrogel. (D) Swelling properties of the PEGda hydrogel. *p < 0.05 2, 4, 8, 16, 24, 168 and 816 h versus 0 h (E, F) MTT-assay of seeded murine endothelial progenitor cells on PEGda
hydrogels. Blue color indicates metabolizing, viable cells. Image (F) represents a higher magniﬁcation of the boxed section highlighted in image (E). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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centration of the supernatant was determined after 0, 2, 4, 8, 12,
24, 48 and 168 h. An initial burst was noted, followed by a sus-
tained BSA release over 7 days. Furthermore, different release
proﬁles emerged depending on the concentration of I 2959. A
decrease in I 2959 concentration resulted in an increased BSA
release. The cumulative release of BSA after 168 h ranged from
16.8  11.3 mg/ml BSA (1.9% of the amount incorporated) using
5000 mg/ml of I 2959, 127.5  9.7 mg/ml BSA (14.4% of the amount
incorporated) using 1000 mg/ml of I 2959, to 156.1  9.7 mg/ml
(17.7% of the amount incorporated) when 750 mg/ml of I 2959
were used. The highest amount of protein release after 168 h was
obtained using 750 mg/ml I 2959. Therefore, this concentration
was deﬁned as suitable for our further experiments.
A human IgG ELISA assay kit was used to determine the cu-
mulative SDF1-GPVI concentration in the collected supernatants
after 48, 96 and 168 h. Release proﬁles of SDF1-GPVI showed a slow
release with cumulative release concentrations yielding
0.13  0.04 mg/ml for hydrogels that were prepared using 3.75 mg
SDF1-GPVI and 0.34  0.04 mg/ml using 7.5 mg SDF1-GPVI respec-
tively after 168 h (Fig. 3B). The release proﬁle of 3.75 mg SDF1-GPVI
showed a decrease of 0.001 mg/ml in protein concentration be-
tween 96 and 168 h, resulting in 3.5% cumulative release of the total
protein amount used for hydrogel preparation. The addition of7.5 mg SDF1-GPVI prior to hydrogel formation lead to a constant
increase in released SDF1-GPVI, with a total amount of 4.5% after
168 h. Furthermore, release proﬁles of hydrogels containing 7.5 mg
SDF1-GPVI depicted signiﬁcantly higher concentrations of released
protein at all three time points (p < 0.05, 7.5 mg versus 3.75 mg
SDF1-GPVI).
3.3. GPVI binding capacity after hydrogel release
A GPVI binding assay was performed to verify proper diffusion
out of the polymer network and to prove unaffected collagen-
binding afﬁnity of the GPVI domain via targeted binding to Col
I after the UV gelation process (Fig. 4). Laminins are glycoproteins
that are highly present in the basement membrane of human
artery vessel walls [35] (Fig. 4A,B). Similarly to BSA, laminin-111
did not bind SDF1-GPVI and hence served as negative control in
the testing of the GPVI domain’s bioactivity and speciﬁcity to-
wards Col I (Fig. 4C,D). Binding signals of biotinylated SDF1-GPVI
on Col I and BSA were compared and reached statistical signiﬁ-
cance at a concentration of 1.25 mg/ml SDF1-GPVI (p ¼ 0.006;
SDF1-GPVI binding to Col I versus BSA) (Fig. 4C). When compared
to laminin-111, GPVI binding to Col I reached statistical signiﬁ-
cance at a concentration of 0.625 mg/ml SDF1-GPVI (p ¼ 0.019,
Col I versus laminin-111) indicating a lower background signal on
Fig. 3. Release proﬁles of BSA and SDF1-GPVI. (A) Bradford assay of released BSA from
PEGda hydrogels with varying I 2959 (750, 1000, 5000 mg/ml) concentrations. For these
experiments a total amount of 1600 mg BSAwas integrated. (B) A human IgG-ELISAwas
employed to determine the amount of released SDF1-GPVI via its IgG domain. The
release proﬁles depend on the loading amount of SDF1-GPVI (3.75 or 7.5 mg/ml). The I
2959 concentration is 750 mg/ml. A sustained protein release is observable using an
incorporated amount of 7.5 mg SDF1-GPVI. *p < 0.05, 7.5 mg versus 3.5 mg SDF1-GPVI.
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from the PEGda hydrogels after 2 days showed signiﬁcantly
higher binding signals to Col I when compared to laminin-111
(Col I 1.55  0.07 versus laminin-111 1.07  0.05;
p ¼ 2.5  E17) (Fig. 4D). Binding signals to Col I remained
signiﬁcantly higher after a period of 6 days (Col I 1.20  0.09
versus laminin-111 0.92  0.07; p ¼ 0.000001); however, overall
reduced binding signal intensities were observed from day 2 to
day 6, indicating an increasing loss of GPVI binding capacity over
time (Fig. 4D).Fig. 4. (A, B) Immunoﬂuorescence staining of an adult human artery vessel wall: (A)
negative control; (B) laminins are immunostained in red, elastin autoﬂuorescence is
shown in green, cell nuclei are depicted in white. (C) An ExtraAvidin coupled ELISA
using biotinylated SDF1-GPVI shows the different binding afﬁnities of GPVI to Col I,
BSA and laminin-111. *p < 0.05, Col I versus laminin-111, **p < 0.05, Col I versus BSA.
(D) GPVI binding signal intensity of the released SDF1-GPVI to Col I. Laminin-111 serves
as negative control. *p < 0.05. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)3.4. SDF1-GPVI exhibits a functional SDF1 domain after hydrogel
release
CXCR4-expressing ECFCs (Fig. 5A,B) were utilized to deter-
mine the SDF1 domain binding potential of released SDF1-GPVI.
The IgG2 domain of SDF1-GPVI served as antigen epitope for
binding of the detection antibody, enabling veriﬁcation of protein
binding to the cells (Fig. 5CeE). Fluorescence expression was
quantiﬁed as GVI per cell, which allowed the comparison of the
binding signals of fresh and released SDF1-GPVI (Fig. 5F).
Signiﬁcantly higher ﬂuorescence intensities were identiﬁed in
the released SDF1-GPVI samples when compared to the negative
controls (0.12  0.01 versus 0.09  0.02; p ¼ 0.0003). No sig-
niﬁcant difference was detected between the released SDF1-GPVI
samples and the positive controls (freshly supplemented SDF1-
GPVI). This result was highly reproducible (Suppl. Fig. 1) and
indicates that neither the hydrogel fabrication procedure nor
the diffusion out of hydrogels signiﬁcantly impact protein
functionality.4. Discussion
It has been previously reported that only 5e10% of injected cells
survive and can integrate within the myocardium due to the harsh
infarct environment post MI [36]. Ziegler et al. demonstrated that
the recombinant bi-speciﬁc protein SDF1-GPVI is able to improve
cardiac function after transient myocardial ischemia in a mouse
model. In detail, homing of BMPCs to the site of infarction and
subsequent neovascularization was enhanced, resulting in an
improved ejection fraction in comparison to the control group that
was treated with the Fc-fragment of immunoglobulin G2 (FcIgG2)
of SDF1-GPVI [13]. An accumulation of CXCR4-positive cells was
observed after 5 days in the infarct zone of the SDF1-GPVI-treated
animals; however, neither the presence of SDF1-GPVI nor CXCR4-
expressing cells were detectable after 28 days [13].
The quality of SDF1-induced BMPC homing is highly dependent
on the level of CXCR4 surface expression on the BMPCs [37]. Pre-
vious studies demonstrated that SDF1 expression is up-regulated in
Fig. 5. (A, B) Immunoﬂuorescence staining of ECFCs: (A) IgG control; (B) CXCR4 is highly expressed (red). Cell nuclei are stained with DAPI (white). (CeE) SDF1-domain binding
afﬁnity to CXCR4 of ECFCs (green): (C) positive control using fresh SDF1-GPVI, (D) incubation with DPBS as negative control and (E) released SDF1-GPVI. Cell nuclei are displayed in
white. (F) Corresponding semi-quantiﬁcations are depicted as gray value intensities (GVI). *p< 0.01 released SDF1-GPVI versus negative control. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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BMPCs reaches its peak 4e7 days in delay [37]. Additionally, SDF1
expression in the myocardium declines 4e7 days after MI [38].
Therefore, a prolonged presence of SDF1 in the myocardium may
enhance BMPC homing to the site of MI. Moreover, the therapeutic
effect of chemokines as homing factors is mainly dependent on a
concentration gradient. Effective BMPC recruitment via SDF1 can be
achieved by a sustained delivery from hydrogels that supports the
prolonged formation of a concentration gradient [24]. In the pre-
sent study, we aimed to generate a PEGda hydrogel that can serve
as a reservoir for SDF1-GPVI bi-speciﬁc protein, which can poten-
tially allow a controlled and sustained release of SDF1-GPVI,
therefore enabling the maintenance of a concentration gradient
over a prolonged time period. Similar to our results, several studieshave demonstrated the release of SDF1 from hydrogels with an
initial burst release followed by a slower sustained release over 7
[14,22,24] or 21 days [39]. As higher dosages of SDF1 have been
identiﬁed to be crucial for BMPC mobilization from the bone
marrow [40], this burst release is advantageous. The fast release of
proteins after the hydrogel has been placed into release medium is
possibly caused by the entrapment of large amounts of encapsu-
lated protein on the surface of the hydrogel during the fabrication
process [41]. In our study, different BSA and SDF1-GPVI release
proﬁles can be explained by the differences in molecular weight
(BSAw66 kDa versus SDF1-GPVIw130 kDa) in combination with a
relatively low incorporated protein concentration of 3200 mg/ml
BSA and either 50 or 100 mg/ml SDF1-GPVI. It has been previously
reported that a reduction in protein concentration in combination
M.K. Schesny et al. / Biomaterials 35 (2014) 7180e71877186with an increase in drug molecular weight can result in a deceler-
ated drug release due to reduced diffusion kinetics [42]. Moreover,
the average surface area of the SDF1-GPVI containing hydrogels
was 1% of the surface area of BSA-loaded hydrogels. This could
further suggest a decline in the release of SDF1-GPVI as it has been
reported that smaller surface areas lead to a delayed release [42],
which is consistent with our results. The release proﬁle of hydro-
gels loaded with 3.5 mg SDF1-GPVI showed no sustained release
over 7 days indicating that the protein loading concentration is too
low for the desired application. However, a constantly increasing
release of SDF1-GPVI could be observed from the hydrogels loaded
with 7.5 mg SDF1-GPVI with supernatant concentrations of
0.22  0.01 mg/ml after 96 h and 0.34  0.03 mg/ml after 168 h.
Previous in vitro studies demonstrated that BMPCmigration is most
effective at concentrations ranging from 0.05 to 0.25 mg/ml SDF1
[39]. Therefore we hypothesize that the concentrations of SDF1-
GPVI in the supernatant of PEGda hydrogels loaded with 7.5 mg
SDF1-GPVI are sufﬁcient for BMPC homing during the observed
time frame.
The percentage of released protein is also inﬂuenced by the
concentration of the incorporated protein. We observed that by
incorporating low protein concentrations, the cumulative release
after 168 h was 3.6% for 50 mg/ml and 4.5% for 100 mg/ml SDF1-
GPVI. Mechanisms of protein immobilization to the hydrogel,
which occur during the crosslinking process, include free radical-
induced protein conjugation or the reaction of acrylate groups
with lysine groups of the proteins via Michael-type addition [43].
Photoinitiator concentration and acrylate groups deﬁne the
amount of immobilized protein. Maintaining these concentrations
results in an immobilized protein amount that is constant irre-
spective of the incorporated protein concentration [15]. Further-
more, the immobilized protein molecular weight plays a crucial
role in its diffusion kinetics, as drug diffusion decelerates at
increasing molecular weight [44]. Consistent with previous reports
[15], we veriﬁed that protein diffusion could be decelerated by
increasing the concentration of I 2959. This effect is due to a higher
crosslinking density and mass-swelling ratio of the hydrogel
resulting in a slower protein release [15] that enables the adapta-
tion of the release proﬁle to patient-tailored parameters. We
further identiﬁed a concentration of 750 mg/ml I 2959 as the min-
imal concentration necessary for the formation of a solid gel, while
allowing the fastest drug release. The photoinitiator concentration
used for the crosslinking of PEGda is a critical parameter. Previous
studies have shown that it correlates with the amount of free
radicals generated during UV crosslinking [45,46]. In turn the free
radicals attack proteins [39,46e48], nucleic acids [48,49] and cell
membranes [50] and subsequently lead to a reduced protein
bioactivity and cytotoxic effects. The cytotoxicity of I 2959 has been
discussed intensively as some studies demonstrated that it is a
suitable photoinitiator for the fabrication of cell-encapsulating
hydrogels [45]. Others reported that I 2959 depicts cytotoxic ef-
fects dependent on the cell type [50]. Furthermore, acrylate groups
have been identiﬁed as a source of potential cytotoxicity [51].
MEPCs cultured on the surface of the photo-crosslinked PEGda
hydrogels generated in this study were viable after a culture period
of 4 days. This might also be due to the relatively low concentration
of 750 mg/ml I 2959 which was used to photo-crosslink PEGda
chains. Higher photoinitiator concentrations were described as
cytotoxic [52].
Several studies have demonstrated a reduction in protein
bioactivity after release from photo-crosslinked hydrogels
[39,46,48]. Whereas the exposure to low UV light intensities
showed no signiﬁcant impairment of protein quality [48], high
intensity UV light exposure of 100 mW/cm2 has been reported to
negatively impact protein quality via photo-oxidation and theformation of protein aggregates [46]. PEGda hydrogels used in this
study were crosslinked using the minimal UV light intensity of
5 mW/cm2 for solid gel formation in combination with I 2959,
which contributed to a preserved protein bioactivity. We conclude
that using the minimal concentration of I 2959 and UV light
exposure is advantageous in order to preserve protein bioactivity.
Triggered by UV light irradiation, free radicals can be formed
during the dissociation of I 2959. Their insufﬁcient selectivity leads
to modiﬁcations of amino acids, which in turn might destroy the
protein structure by disruption of peptide bonds and the addition of
crosslinks between proteins [48]. We observed that released SDF1-
GPVI bound speciﬁcally to Col I, which indicates a preserved GPVI
functionality. However, a decline in GPVI binding signal intensity
could be observed for released SDF1-GPVI from day 2 until day 6. As
the estimated half-life of SDF1-GPVI is 48 h [13], a fraction of
released SDF1-GPVI might have lost its binding capacity to Col I
after 6 days. The SDF1 domain showed speciﬁc binding to CXCR4-
positive cells without a culture time-dependent impaired binding
intensity when compared to fresh SDF1-GPVI.
The combination of parameters used for the fabrication of the
PEGda hydrogels was chosen with regard to minimal free radical
and UV light exposure, whichmay explain the preserved bioactivity
of the bi-speciﬁc protein. Furthermore, the acrylate groups of
PEGda support protein bioactivity maintenance [46]. This positive
effect can be attributed to the conversion of free radicals into less
reactive and destructive species by acrylate groups and their
function as free radical scavengers [46,48]. In this study, PEGda
with an average molecular weight of 6 kDa was employed resulting
in a relatively high polymer solution viscosity. Viscous polymer
solutions act as cages that protect incorporated proteins from free
radical attacks [46]. Thus, the stimulation of BMPCs via G-CSF
administration in combination with the release of functional SDF1-
GPVI from the generated PEGda hydrogel may result in enhanced
rates of integrated BMPCs in the myocardium. This strategy is an
interesting alternative approach to the currently used systemic
injection of SDF1-GPVI and should be investigated with an in vivo
MI model.
5. Conclusion
In this study, a cytocompatible photo-crosslinked PEGda
hydrogel enabled a sustained release of the bi-speciﬁc protein
SDF1-GPVI in vitro. Protein release proﬁles were tunable by the
protein loading dose and the degree of crosslinking. Binding of the
GPVI domain to Col I as well as speciﬁc binding of the SDF1 domain
to CXCR4-positive cells after SDF1-GPVI release was successfully
demonstrated. We determined that the bioactivity of the hydrogel-
released SDF1-GPVI was comparable to fresh SDF1-GPVI, indicating
that no loss of functionality occurred during the protein encapsu-
lation via UV light. The PEGda hydrogels designed in this study can
serve as suitable encapsulating systems for bi-speciﬁc proteins and
could be used for the release of therapeutics. The design of an
effective SDF1-GPVI release system might support angiogenesis in
injured myocardium, while restoring cardiac function and thus
serve as an attractive alternative for the therapeutic treatment of
ischemic cardiovascular disease.
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